Clinical trial reporting still dangerously inadequate, says BMJ
This article was originally published in Scrip
The British Medical Journal (BMJ) has published seven research papers providing a damning indictment of current practice in clinical trial reporting. According to the accompanying editorial by senior research fellow Richard Lehman and clinical epidemiology editor Elizabeth Loder, the articles confirm that "a large proportion of evidence from human trials is unreported, and much of what is reported is done so inadequately". As they note, this leads to unnecessary harm to patients and costs to health systems.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.